FSD Pharma Inc.
HUGENASDAQHealthcare
$0.09
$-0.01(-10.10%)
Market Cap$66671
P/E Ratio—
52W High$109.1935
52W Low$0.087
FSD Pharma Inc. (HUGE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HUGE · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 14, 2024EPS Actual
-$0.08
Est. -$0.06 · -33.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 14, 2024
After Market Close
▼ Miss EPS
HUGE reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2025 | Aug 12, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 12, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 26, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 12, 2024 | -$0.06 | — | — | — | $0.00B | — |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$0.06 | -$0.08 | -33.3% | — | $0.00B | — |
| — Q2 FY2024 | May 14, 2024 | -$0.05 | -$0.05 | +0.0% | — | $0.00B | — |
| ▲ Q1 FY2024 | Mar 28, 2024 | -$0.14 | -$0.04 | +71.4% | — | — | — |
| ▲ Q4 FY2023 | Nov 14, 2023 | -$0.14 | -$0.03 | +78.6% | — | — | — |
Q3 FY2025
Aug 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 26, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 12, 2024
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$0.08
EPS Est.
-$0.06
EPS Surpr.
-33.3%
Revenue
—
Q2 FY2024
May 14, 2024
EPS Actual
-$0.05
EPS Est.
-$0.05
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2024
Mar 28, 2024Beat
EPS Actual
-$0.04
EPS Est.
-$0.14
EPS Surpr.
+71.4%
Revenue
—
Q4 FY2023
Nov 14, 2023Beat
EPS Actual
-$0.03
EPS Est.
-$0.14
EPS Surpr.
+78.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q3 FY2025 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2025 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q1 FY2025 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q4 FY2024 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2024 | $-0.06 | $-0.06 | $-0.06 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2024 | Aug 14, 2024 | -33.3% | $6.50 | $5.84 | -10.15% |
| ▲ Q2 FY2024 | May 14, 2024 | +0.0% | $24.72 | $22.62 | -8.50% |
| ▲ Q1 FY2024 | Mar 28, 2024 | +71.4% | $46.15 | $46.51 | +0.78% |
| ▲ Q4 FY2023 | Nov 14, 2023 | +78.6% | $67.60 | $70.85 | +4.81% |
| — Q3 FY2023 | Jul 20, 2023 | — | $74.10 | $73.45 | -0.88% |
| — Q2 FY2023 | May 12, 2023 | — | $70.20 | $70.85 | +0.93% |
| — Q1 FY2023 | Mar 31, 2023 | — | $104.65 | $100.75 | -3.73% |
| — Q4 FY2022 | Nov 11, 2022 | — | $59.42 | $69.55 | +17.05% |
Q3 FY2024-10.15%
Report Date
Aug 14, 2024
EPS Beat/Miss
-33.3%
Price Before
$6.50
Price After
$5.84
Q2 FY2024-8.50%
Report Date
May 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$24.72
Price After
$22.62
Q1 FY2024+0.78%
Report Date
Mar 28, 2024
EPS Beat/Miss
+71.4%
Price Before
$46.15
Price After
$46.51
Q4 FY2023+4.81%
Report Date
Nov 14, 2023
EPS Beat/Miss
+78.6%
Price Before
$67.60
Price After
$70.85
Q3 FY2023-0.88%
Report Date
Jul 20, 2023
EPS Beat/Miss
—
Price Before
$74.10
Price After
$73.45
Q2 FY2023+0.93%
Report Date
May 12, 2023
EPS Beat/Miss
—
Price Before
$70.20
Price After
$70.85
Q1 FY2023-3.73%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$104.65
Price After
$100.75
Q4 FY2022+17.05%
Report Date
Nov 11, 2022
EPS Beat/Miss
—
Price Before
$59.42
Price After
$69.55
Avg Beat Reaction-0.97%
Avg Miss Reaction-10.15%
Beat Rate3 / 8 quarters
Largest Move+17.05% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HUGE ends December
FSD Pharma Inc. (HUGE) most recently reported earnings on August 14, 2024 for Q3 FY2024, posting EPS of $-0.08 — missing the analyst consensus of $-0.06 by -33.3%. The next HUGE earnings date is expected around September 1, 2026.
Each quarter, investors track HUGE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HUGE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HUGE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HUGE earnings · 5 questionsFSD Pharma Inc.'s next earnings report is expected around September 1, 2026. HUGE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HUGE historically reports after market close (AMC).
HUGE earnings datewhen is HUGE earningsHUGE next earnings datewhen does HUGE report earningsHUGE earnings calendar
▸ Source: FMP · FSD Pharma Inc. SEC filings · US GAAP · FSD Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026